Form D · Biotechnology
Ayala Pharmaceuticals, Inc.
Monmouth Junction, NJ · CIK 0001100397
Offering snapshot reported Nov 2, 2023 · SEC filing
- Reported sold
- $434K Offering amount: $434K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 2, 2023 | Initial | $433,825 | No comparison | 3 | SEC filing |
| Feb 11, 2022 | Initial | $4,750,000 | No comparison | 6 | SEC filing |
| Apr 28, 2021 | Initial | $11,093,521 | No comparison | 2 | SEC filing |
| Dec 13, 2012 | Initial | $0 | No comparison | 1 | SEC filing |
| Jun 6, 2012 | Initial | $715,000 | No comparison | 8 | SEC filing |
| May 29, 2012 | Initial | $4,473,673 | No comparison | 29 | SEC filing |
| Feb 24, 2012 | Initial | $1,047,500 | No comparison | 12 | SEC filing |
| Nov 15, 2011 | Initial | $1,977,500 | No comparison | 12 | SEC filing |
| May 27, 2011 | Initial | $6,016,250 | No comparison | 24 | SEC filing |
| Nov 15, 2010 | Initial | $835,000 | No comparison | 10 | SEC filing |
| Jul 30, 2010 | Initial | $7,500,000 | No comparison | 1 | SEC filing |
| Oct 22, 2009 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Oct 5, 2009 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Oct 1, 2009 | Initial | $961,650 | No comparison | 7 | SEC filing |
| Oct 29, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 10, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-496373
Amounts above based on $0.93 per share, the closing price of the common stock on OTCQX on date of merger.
Shares of common stock
Source: Form D, filed Nov 2, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Roni A. Appel | Director |
| Kenneth Berlin | Director, Executive |
| Ken A. Berlin | Director, Executive |
| Richard Berman | Director |
| Vered Bisker Leib | Director |
| Yuval Cabilly | Director |
| Fredrick Cobb | Executive |
| Igor Gitelman | Executive |
| Roy Golan | Executive |
| Murray A. Goldberg | Director |
| Andres Gutierrez | Executive |
| Samir Khleif | Director |
| Bridget Martell | Director |
| Thomas Mckearn | Director |
| Thomas L. Mc Kearn | Director |
| Thomas Moore | Director, Executive |
| Pini Orbach | Director |
| James Patton | Director |
| Mark J. Rosenblum | Executive |
| John Rothman | Executive |
| David Sidransky | Director |
| Robert Spiegel | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9 Deer Park Drive Suite K 1
Monmouth Junction, NJ, 08852
Monmouth Junction, NJ, 08852